Cite
HARVARD Citation
Miller, A. et al. (n.d.). 225. Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections. Open forum infectious diseases. p. . [Online].